Objectives: To characterize the AmpC-type b-lactamases produced by Escherichia coli clinical isolates.
Introduction
Escherichia coli naturally produces a chromosome-encoded AmpC at a very low level due to a weak promoter and the effect of a transcriptional attenuator. 1 Spontaneous mutations in the promoter region of the ampC gene in E. coli may induce constitutive overproduction of the AmpC b-lactamase and confer resistance to narrow-spectrum cephalosporins.
cephalosporinase sequences that are in the vicinity of the active site, the V loop, the H-2 helix, the H-9 helix, the H-10 helix, the R2 loop and the H-11 helix. 5 The objective of the present work was to characterize the AmpC b-lactamases expressed by clinical E. coli isolates that displayed a resistance phenotype consistent with the production of a cephalosporinase, recovered during a 1 year period in a French hospital and to analyse their clonal relationship.
Materials and methods

Bacterial strains
Clinical isolates were identified using API 20E system (bioMérieux, Marcy-l'É toile, France). E. coli TOP10 and azide-resistant E. coli J53 were used for transformation and conjugation experiments, respectively. 6 Study design E. coli clinical isolates that were recovered at the Bicêtre hospital (Le K.-Bicêtre, France) in 2006 and that displayed a resistance phenotype consistent with an increased AmpC production on the basis of resistance to amoxicillin and cefalotin, which was not antagonized by clavulanic acid addition, were included in this study. AmpC production was further confirmed using cloxacillin (200 mg/ L)-containing plates, which specifically inhibit class C b-lactamases and restore susceptibility to cephalosporins. 5 Only non-duplicate isolates were retained in this study.
Molecular typing
The 34 isolates were compared by enterobacterial repetitive intergenic consensus (ERIC) PCR using primer ERIC2. 7 The isolates that displayed identical patterns were subsequently genotyped by PFGE analysis. 8, 9 Phylotyping analysis
The PCR-based phylotyping analysis described by Clermont et al. 10 was applied to the clinical isolates included in this study. The method, which uses a combination of two genes (chuA and yjaA) and an anonymous DNA fragment, allows the determination of the main phylogenetic groups of E. coli (these being A, B1, B2 and D).
Plasmid DNA extraction, conjugation and transformation experiments
Plasmid DNA was extracted using the plasmid Midi kit (Qiagen, Courtaboeuf, France). Transfer by conjugation or transformation of b-lactam resistance marker was attempted from ESAC b-lactamase-producing E. coli isolates as described previously.
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Antimicrobial agents and MIC determination
The antibiotic agents and their sources have been described elsewhere. 12 MICs were determined by an agar dilution technique on Mueller -Hinton agar (Sanofi-Diagnostics Pasteur, Paris, France) with an inoculum of 10 4 cfu per spot and were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute.
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Amplification of the ampC genes and sequence analysis Total DNA was extracted as described previously. 12 Genes encoding six phylogenetic groups of acquired AmpC enzymes were sought using multiplex PCR assays.
14 The plasmid-borne genes of the bla CMY/LAT lineage were entirely sequenced using primers Promþ (5 0 -TGCTCTGTGGATAACTTGC-3 0 ), PreCMY-2b (5 0 -TGCGC ATGGGATTTTCCTTG-3 0 ) and the primer pair, CITMR and CITMF, used in the multiplex PCR described previously. 14 PCR amplifications of ampC genes were performed with primers Int-B2 (5 0 -TTCCTGATGATCGTTCTGCC-3 0 ) and Int-HN (5 0 -AAAA GCGGAGAAAAGGTCCG-3 0 ), yielding a 1315 bp amplification product that contained the entire ampC gene of E. coli, including its own promoter sequence. Sequence analyses were performed with PAUP version 3.1.1 and software available at the internet web sites www.ncbi.nlm.nih.gov and http://www.ebi.ac.uk/clustalw/.
Cloning of b-lactamase genes
Amplification with primers Int-B1 (5 0 -TTTTGTATGGAACC AGACC-3 0 ) and Int-HN of ampC genes from E. coli ECB9 to E. coli ECB33 and E. coli BER gave PCR products of 1120 bp containing only the coding regions without their own promoter. These PCR products were cloned into pCR-BluntII-Topo (Invitrogen), and the recombinant plasmids were subsequently transformed into E. coli strain TOP10 as described previously. 6 
Nucleotide sequence accession numbers
The nucleotide sequence of bla AmpC genes of E. coli ECB33 has been deposited in EMBL nucleotide sequence database under accession no. EF661829.
Results
AmpC producer detection
Thirty-four out of 2800 E. coli isolates that were recovered at the Bicêtre hospital in 2006 met the selection criteria and were included in this study. These isolates were retained because their resistance phenotype was consistent with AmpC b-lactamase production. They were resistant to narrow-spectrum cephalosporins; this resistance was not antagonized by clavulanic acid, whereas the susceptibility to these compounds was restored using cloxacillin-containing plates. Twenty-four isolates were recovered from urine samples, 1 from blood culture and 9 from purulent exudates.
Detection of plasmid-mediated cephalosporinase genes
Plasmid-mediated ampC genes were detected in eight E. coli isolates, ECB1 to ECB8 (Table 1) . A multiplex PCR gave rise to a 350 bp amplicon from isolate ECB1, which was in agreement with the presence of a gene of the bla ACC lineage. Sequencing of the entire gene showed 100% identity with the bla ACC-1 gene. Multiplex PCR for detection of PMAC b-lactamase genes yielded an amplicon whose size (760 bp) was consistent with the presence of a gene of the bla CMY/LAT lineage from isolates ECB2 to ECB8. PCR mapping using primers Promþ and PreCMY2b, which are complementary to the flanking regions of other bla CMY-2 -like genes, yielded amplification products of 1.7 kb from isolates ECB2 to ECB8, suggesting that in all of them the bla CMY gene was located downstream of ISEcp1. Sequencing of the entire gene revealed the presence of an identical allele, which encoded the b-lactamase CMY-2. All the E. coli isolates producing PMAC b-lactamases belonged to phylogenetic group B1 ( Table 1) .
Analysis of the chromosome-borne b-lactam resistance determinants
Sequence analysis of the chromosomal ampC genes revealed mutations in the promoter regions of 26 isolates, ECB9 to ECB33 and E. coli BER (Table 1) , which created promoters that more closely resembled the E. coli consensus promoter. 1 Mutations that created an alternative displaced promoter only occurred in E. coli isolates of the group A or B1 (Table 1) . Changes included C!T mutation at position 242, which changed CTGACA to TTGACA to create a novel 235 box, and a G!A transition at position 218, which changed TGTCGT to TATCGT to create a novel 210 box. 1 The alternative 235 and 210 sequences were separated by 17 bp. The mutations in the ampC promoter region at positions 211, 232 or the insertion of one or two nucleotides between the 235 and 210 boxes, which have already been described in previous studies, 1,2,15 were more frequently identified in isolates of the group B2 or D ( Table 1) .
The analysis of the deduced amino acid sequences of the chromosome-borne cephalosporinases revealed that AmpC ECB29 to AmpC ECB33 and AmpC BER that were produced by isolates ECB29 to ECB33 and E. coli BER, respectively, and presented structural modifications in the H-9 helix or in the R2 loop [ Table 1 and Figure S1 ; Figure S1 is available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. The amino acid replacement H296P, which occurred in AmpC ECB29, AmpC ECB30 and AmpC ECB31, and the S287N replacement, which occurred in AmpC ECB32, have been already reported. 6 The insertion of two residues inside the H-10 helix, which 
occurred in AmpC BER, was recently characterized, 16 whereas AmpC ECB33 presented the peculiarity of a single amino acid insertion in the H-9 helix due to the duplication of Ile-283. This is the first report of an insertion inside the H-9 helix as a source of extended-spectrum hydrolysis.
Transferability and genetic support of the bla AmpC genes from isolates ECB9 to ECB33 and E. coli BER Plasmid-mediated ampC genes were transferred by conjugation to E. coli J53 from clinical isolates ECB1 to ECB8. Conjugation and transformation experiments were also performed to determine whether the cephalosporin resistance marker could be transferred from E. coli ECB9 to ECB33 and E. coli BER. Despite multiple attempts, this resistance marker could not be transferred, thus indicating a chromosomal location of the ampC genes as very likely in those isolates.
Susceptibility testing of E. coli clinical isolates
The MIC values for E. coli clinical isolates are presented in Table 2 .
The E. coli clinical isolates ECB9 to ECB16, ECB18 to ECB23, ECB27 and ECB28 remained fully susceptible to extended-spectrum cephalosporins (ESCs), whereas E. coli clinical isolates ECB1 to ECB8, ECB17, ECB24 to ECB26, ECB29 to ECB33 and E. coli BER presented a reduced susceptibility to ESCs and to aztreonam ( Table 2) . No difference between MICs of imipenem and ertapenem was noticed.
Functional characterization of chromosome-borne AmpC b-lactamases
The functional properties of chromosomal cephalosporinases, which were overexpressed due to mutations in the promoter regions, were investigated by cloning the coding regions into the plasmid vector TOPO-Blunt followed by expression in E. coli TOP10. MIC values were determined for each clone and are presented in Table 3 . Clones expressing AmpC ECB8 to AmpC ECB28 presented similar patterns of resistance and remained fully susceptible to ESCs, thus indicating that these enzymes were narrow-spectrum cephalosporinases. E. coli recombinant clones producing AmpC ECB29 to AmpC ECB33 and AmpC BER were resistant to ceftazidime and presented reduced susceptibility to other ESCs, such as cefotaxime and cefepime, and to aztreonam, thus indicating that they were ESAC b-lactamases. The recombinant clones remained fully susceptible to imipenem and ertapenem without reliable difference between the MICs of these two compounds.
Genotyping analysis of AmpC-producing isolates
Genotyping by random amplification of polymorphic DNA showed that isolates were non-clonally related except E. coli ECB5, ECB6, ECB7 and ECB8, which presented identical amplification patterns (data not shown). Analysis of the XbaI-digested DNA fragments by PFGE confirmed this clonal relationship (data not shown).
Discussion
AmpC-producing E. coli isolates constitute a relevant epidemiological threat in hospitals. 17 This work sheds new light on the prevalence of E. coli clinical isolates that produced variant cephalosporinases with a broadened hydrolysis spectrum. The ESAC b-lactamases have likely evolved from wild-type cephalosporinases by structural modifications in peculiar secondary structures, i.e. the H-9 helix and the R2 loop containing the H-10 helix, which are both involved in the binding of ESCs. 18 These structural changes have been reported in previous studies, except for the amino acid duplication in the helix H-9, which is reported here for the first time. 6, 16 Clinical isolates which overproduced a chromosomal wildtype cephalosporinase due to mutations in the ampC promoter region remained fully susceptible to ESCs (MICs 4 mg/L), although discrepancies, which could be attributed to the promoter strength, were noticed. According to MIC values, the 232 (T!A) and 242 (C!T) substitutions and the insertion of 1 bp between the 235 and the 210 boxes led to a higher level of expression than the 211 (C!T) substitution or a 2 bp insertion. These phenotypic variations were in agreement with the molecular results recently obtained by Tracz et al. 19 using RT -PCR. Almost all the chromosomal AmpC-overexpressing isolates of group A or B1 had the 242 (C!T) transition in their ampC promoter region whereas this mutation was never observed in the ampC promoter of group B2 or D. 6 Moreover, this substitution was always associated with a G!A transversion at position 218, thus giving rise to an alternative displaced strong promoter. 1 It is noteworthy that the adenine at position 218 had already been described without the 242 (C!T) mutation in several AmpC-non-overexpressing isolates. 20 Therefore, it seems that the nucleotide variability at position 218 relies on a natural polymorphism which could match with the phylogenetic groups, thus providing a selective advantage to the isolates of groups A and B1. Further studies are necessary to confirm this hypothesis.
As indicated above, the wild-type chromosomal AmpCproducing isolates were fully susceptible to ESCs, except E. coli ECB17, ECB24, ECB25 and ECB26. However, the corresponding recombinant clones of these clinical isolates were all fully susceptible to ESCs, thus indicating that an additional non-enzymatic mechanism of resistance, such as loss of outer membrane porins, 21 was likely to be involved in those clinical isolates.
This study identified the prevalence of plasmid-mediated cephalosporinases of the CMY/LAT-type lineage among the PMAC-producing E. coli isolates in our hospital. CMY-2 originated from the chromosomal AmpC of Citrobacter freundii and is now widely distributed throughout the world probably due to the spread of conjugative plasmids of the IncA/C type. 2,3,20 -28 Moreover, in several settings, this plasmid-borne resistance marker has been disseminated by epidemics of particular clones. 23, 24 This study revealed that the phenotypic approach failed to differentiate AmpC-type b-lactamases. Most of the CMY-2-and ESAC-producing isolates identified here had increased resistance to cefoxitin and ceftazidime. Moreover, several ESAC-producing a Recombinant clones E. coli TOP10 (pECB9) and E. coli TOP10 (pECB28) produced narrow-spectrum AmpC b-lactamases, whereas E. coli TOP10 ( pECB29), E. coli TOP10 ( pECB32), E. coli TOP10 (pECB33) and E. coli TOP10 ( pBER) produced ESAC b-lactamases with H296P replacement, S287N replacement, amino acid insertion in the helix H-9 or amino acid insertion in the helix H-10, respectively. b Clavulanic acid at 2 mg/L. c Tazobactam at 4 mg/L.
isolates, such as E. coli BER, shared with ACC-producing E. coli isolates, such as E. coli ECB1, the peculiarity of being susceptible to cefoxitin whereas they had reduced susceptibility to ceftazidime and even cefepime. Thus, cefoxitin, ceftazidime and cefepime could not constitute good markers to differentiate between these different mechanisms of resistance to cephalosporins in E. coli.
In conclusion, the prevalence of ESAC and PMAC b-lactamases, 0.21% and 0.28%, respectively, was identical in E. coli clinical isolates from our hospital. Only molecular methods, such as PCR, are able to differentiate chromosomal and plasmid-mediated resistance to ESCs, the latter only being transferable among Enterobacteriaceae.
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